Diligence memo · auto-generated · as of July 2, 2026
CoolTech
CoolTech looks over-valued against its niche peers and is dormant on financing cadence.
Businessfiled
CoolTech operates in Biotechnology, based in BALTIMORE.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
CoolTech has raised $9.1M in disclosed capital across 4 recorded rounds, aggregated from public filings. Its latest round is modeled as Seed (a $1.0M–$4.0M round).
Largest single filing: $3.0M on 2018-07-01.
Most recent recorded round closed around 2020-10-07.
Valuation (modeled)modeled
Provath models CoolTech at approximately $115M (range $2.2M–$839M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Over-valued. Modeled value is 1.79× the median modeled value of Seed Biotechnology companies in 2019–2021 (186 peers) — value vs value, same stage and era. Issuer reports no revenue, yet is modeled well above niche peers.
Financing rhythm & timingmixed
Historic cadence: a new round about every 20 months.
Last raise 5.7 yr ago; this sector typically re-raises about every 14 months.
Silent for over 3× the sector's normal cadence.
The last round stepped up 1.0× from the prior — scaling.
Comparablesmixed
Capital scale ranks ahead of 54% of Biotechnology peers (4293 compared).
Modeled value ranks above 62% of those peers.
Closest niche peers: Novo Biosciences, Inc., Entac Medical, Inc., ReGelTec, Inc., Korro Bio, Inc., TamuroBio Inc..
Peoplefiled
2 named people on file across officers, directors and signatories.
Risks & flagsmixed
Financing has been silent well beyond sector cadence — possibly defunct, acquired, or paused.
Modeled above niche peers — valuation risk on entry.
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.